Never mind the   for quality control problems Sales of prescription drugs to the US by the Indian pharmaceutical industry likely wont take a huge hit at least according to a new report Why Indias generic drug makers remain large suppliers to American consumers writes India Research  Ratings The FDA may have banned imports from  Indian manufacturing plants last year  more than in any other year  but Indian drug makers accounted for  percent of US generic drug imports based on volume and  percent of total generic drug approvals by the agency Moreover the ratings firm believes that the Affordable Care Act will further expand the US market for lowercost generics Already  of prescriptions filled in the US last year were for generics according to the IMS Institute for Healthcare Informatics And so the firm forecasts the Indian pharmaceutical industry should experience compounded annual growth of  for the next five years More on this after the jump